References in periodicals archive ?
Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87).
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Protein kinase activity-dependent inhibition of urokinase-type plasminogen activator gene transcription by cyclic AMP in human pre-B lymphoma cell line RC-K8.
Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.
Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells.
In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
11] Human genes: Try, trypsinogen; MMP2/7/9, matrix-metalloproteinase2/-7/-9; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator receptor; MSH2, Mut S homolog 2; GAPD, glyceraldehyde-3-phosphate dehydrogenase.
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate.
Urokinase-type plasminogen activator (uPA) is a serine protease that catalyzes the conversion of plasminogen to plasmin, an active enzyme that is able to degrade various extracellular matrix proteins and to activate MMPs and growth factors (3).